Clinical trials
Duchenne Muscular Dystrophy clinical trials
Below are recruiting duchenne muscular dystrophy clinical trials, each written for real people, not researchers. We’re tracking 80 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06363526Enrolling by invitation
Digital breathing exercises for children with muscular dystrophy
This trial tests a 5-week digital breathing exercise program for children with Duchenne or Becker muscular dystrophy. It aims to improve lung function using simple exercises done at home.
MálagaAges 5–20 - NCT06290713RecruitingPhase 2
Blood flow and exercise study for Duchenne muscular dystrophy
This trial tests if a medicine that improves blood flow, combined with exercise, can help muscles in boys with Duchenne muscular dystrophy. It is for boys who can still walk and are on a stable steroid medication.
Gainesville, FloridaAges 6 years+ - NCT06270719Enrolling by invitation
Comparing ELEVIDYS to standard care for Duchenne muscular dystrophy
This study compares the gene therapy ELEVIDYS (delandistrogene moxeparvovec) to usual treatments for people with Duchenne muscular dystrophy (DMD). It helps researchers understand how well ELEVIDYS works over time in real-world settings.
Little Rock, ArkansasAges 4 years+ - NCT06138639RecruitingPhase 1/Phase 2
Gene therapy SGT-003 for Duchenne muscular dystrophy
This trial tests a new gene therapy called SGT-003 for children with Duchenne muscular dystrophy. It aims to help the body produce a working version of dystrophin, the protein missing in Duchenne.
Little Rock, ArkansasAges birth–17 years - NCT06147414Recruiting
Blood test for genetic disorders in pregnancy
This study tests a safer blood test to check for certain genetic disorders during pregnancy, instead of an invasive procedure like amniocentesis. It's for pregnant women who are at risk of passing on a known genetic condition.
ParisAges 18 years+ - NCT01484678Recruiting
MRI and body biomarkers study for muscular dystrophy
This study uses MRI scans and blood or other biomarkers to better understand muscular dystrophy in people with Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD). It may help researchers track disease changes and identify measurable markers over time.
Gainesville, FloridaAges 5–62 - NCT05933057RecruitingPhase 3
Givinostat for wheelchair-bound boys with Duchenne muscular dystrophy
This Phase 3 trial tests givinostat to see if it can improve safety and functional outcomes in boys with Duchenne muscular dystrophy who cannot walk. You might be a candidate if you meet age, genetic diagnosis, wheelchair-level mobility, and specific arm-strength/respiratory/heart criteria.
LeuvenAges 9–17 - NCT05019625Recruiting
Study samples for biomarkers in myotonic dystrophy
This study collects blood and, for some people, muscle tissue to look for signs (biomarkers) that can help track and better understand myotonic dystrophy. You may help by providing samples and basic muscle function testing, depending on your age and condition type.
Boston, MassachusettsAges 5 years+ - NCT05016908Recruiting
Testing blood and other fluid markers in Duchenne or Becker
This study looks for signals in blood and other body fluids that may help track Duchenne or Becker muscular dystrophy. It may be helpful for patients by improving how future monitoring tests are developed.
Boston, MassachusettsAges 5 years+ - NCT05715957Enrolling by invitation
Follow-up study for women who carry a DMD gene change
This study follows women who have a confirmed DMD gene mutation (a genetic change related to Duchenne/Becker muscular dystrophy) to learn more about health and muscle-related measurements. Depending on the part of the study, you may be asked to take part in MRI or other assessments.
CopenhagenAges 18 years+ - NCT04906460RecruitingPhase 1/Phase 2
Testing WVE-N531 for Duchenne muscular dystrophy exon 53
This early-phase study tests WVE-N531 in people with Duchenne muscular dystrophy (DMD) whose genetics specifically match an “exon 53” change. It may help by targeting the muscle disease process, and it includes procedures like muscle biopsies and regular heart/lung checks.
Little Rock, ArkansasAges 4–18 - NCT04626674RecruitingPhase 1
Gene therapy for non-ambulatory Duchenne muscular dystrophy
This study tests a gene therapy that aims to help muscles produce a protein they are missing. It is for people with Duchenne muscular dystrophy who are no longer able to walk, and it may help slow the progression of the disease.
Little Rock, ArkansasAges 2 years+ - NCT03373968RecruitingPhase 2/Phase 3
Long-term study of givinostat safety in Duchenne muscular dystrophy
This trial looks at how safely givinostat works over a longer time in people with Duchenne muscular dystrophy (DMD). It mainly checks long-term side effects and tolerability, especially in a specific subgroup of muscle fat levels.
Sacramento, CaliforniaAges 7 years+ - NCT03882827Recruiting
Natural history study of Duchenne muscular dystrophy in young boys
This study follows boys with Duchenne muscular dystrophy over time to better understand how the condition changes and how standard treatments affect health and function. It does not appear to test a new medicine, but it may help doctors plan better future care and studies.
BrusselsAges 4–9 - NCT02413450Enrolling by invitation
Using patient DNA cells to study inherited heart rhythm risks
This study uses your blood or genetic information to make “iPS cells,” lab-grown cells that can help researchers study inherited heart rhythm problems like LQTS, Brugada syndrome, CPVT, or early repolarization syndrome. It may help improve understanding of why these rhythms happen and guide future treatments.
Baltimore, MarylandAges 18–85 - NCT02069756Recruiting
Duchenne and Becker muscular dystrophy registry
This registry collects information about people with Duchenne or Becker muscular dystrophy, including women who carry the gene (with or without symptoms). It may help researchers better understand the condition and plan future studies.
Washington D.C., District of ColumbiaAges Any age - NCT07436143Recruiting
Posture and quality of life in Duchenne muscular dystrophy
This study looks at how different body positions affect daily life and well-being in children with Duchenne muscular dystrophy. It may help find ways to improve comfort and function.
Lahore, Punjab ProvinceAges 5–9 - NCT07423026Recruiting
Remote study using technology to track DMD in young boys
This study uses remote technology, like apps or wearable devices, to monitor motor skills and development in boys with Duchenne muscular dystrophy (DMD). It aims to find better ways to measure how the disease progresses over time without requiring frequent clinic visits.
OxfordAges 1–3 - NCT06224660RecruitingPhase 1
Gene therapy for heart problems in Duchenne muscular dystrophy
This trial tests an experimental therapy for heart weakness caused by Duchenne muscular dystrophy. It aims to improve how heart cells handle calcium to protect heart function.
Kansas City, KansasAges 18 years+ - NCT06925269Recruiting
DMD Voice: Interviews with patients and caregivers
This study invites people with Duchenne muscular dystrophy (DMD) and their caregivers to share their experiences through interviews. It focuses on those who have been taking the medication Givinostat for at least two years, or caregivers of patients with limited arm movement.
Yardley, PennsylvaniaAges 10 years+ - NCT07058662RecruitingPhase 1/Phase 2
Gene therapy study for Duchenne muscular dystrophy in boys 4-8
This study tests a new gene therapy called BBM-D101 for boys with Duchenne muscular dystrophy. The goal is to see if it is safe and can help improve muscle function. It is for boys aged 4 to 8 who can still walk.
Beijing, Beijing MunicipalityAges 4–9 - NCT06769633RecruitingPhase 2
Study of givinostat in young boys with Duchenne muscular dystrophy
This trial tests an experimental drug called givinostat in boys ages 2 to under 6 years with Duchenne muscular dystrophy (DMD). The study looks at how the drug works in the body and if it is safe, with the goal of finding new treatment options for young children.
BrusselsAges 2–6 - NCT06692426RecruitingPhase 1
Cell therapy for Duchenne muscular dystrophy
This trial tests a new cell-based treatment for Duchenne muscular dystrophy in adults who can no longer walk. The goal is to see if the therapy can help improve muscle function.
Minneapolis, MinnesotaAges 18 years+ - NCT06606340Enrolling by invitation
Long-term study of eteplirsen, golodirsen, or casimersen for DMD
This study follows people with Duchenne muscular dystrophy (DMD) who are taking eteplirsen, golodirsen, or casimersen. It aims to understand how these medicines work in everyday life over a long period.
Little Rock, ArkansasAges Any age
Hear when a new Duchenne Muscular Dystrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for duchenne muscular dystrophy?
- Yes. Clin2 currently lists 80 recruiting duchenne muscular dystrophy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a duchenne muscular dystrophy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a duchenne muscular dystrophy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.